Polysomnographic findings in recently drug-free and clinically remitted depressed patients

Archives of General Psychiatry
A J RushH P Roffwarg

Abstract

Thirteen patients were examined by sleep polysomnograph (PSG) and the dexamethasone suppression test when clinically depressed and later when clinically remitted for six months and no longer receiving antidepressant medication for two to five weeks. None of the PSG variables (rapid eye movement [REM] latency, total sleep time, stage 1 through 4 times, REM time, and REM densities in periods 1 through 3) was significantly changed between symptomatic depression and symptom remission. While symptomatic, 11 of 13 patients exhibited a reduced REM latency (65 minutes or less). After clinical remission, eight of the 11 continued to exhibit reduced REM latencies, whereas the dexamethasone suppression test tended to show nonsuppression only during clinical depression. These data represent either longer-term (ie, slow to normalize) biologic consequences of a depressive episode or biologic antecedents of clinical depression that may herald a return of the depression in individuals vulnerable to recurrence. Whether PSG abnormalities identify clinically remitted patients who are prone to develop another depressive episode requires longitudinal follow-up studies.

Citations

Nov 6, 2013·Pharmacology & Therapeutics·M DreslerF Holsboer
Jul 14, 1999·Journal of Affective Disorders·M E Thase, E S Friedman
Dec 26, 2008·Journal of Child and Adolescent Psychopharmacology·Uma Rao, Russell E Poland
Mar 26, 2011·BMC Neuroscience·Thomas FenzlAlexander Yassouridis
Dec 1, 1993·Journal of Sleep Research·M Berger, D Riemann
Nov 28, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Giovanni Andrea FavaNicoletta Sonino
Jan 1, 1993·Progress in Neuro-psychopharmacology & Biological Psychiatry·A SteigerF Holsboer
Feb 1, 1989·Psychiatry Research·D E GilesB A Etzel
Feb 15, 1997·Biological Psychiatry·S CheetaP Willner
Jan 15, 1995·Biological Psychiatry·A L Sharpley, P J Cowen
Oct 15, 1990·Biological Psychiatry·D E GilesA J Rush
Jun 1, 1993·Biological Psychiatry·K L BensonV P Zarcone
Apr 17, 2001·Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine·J FifieldN Rothfield
Oct 1, 1989·Journal of Neurology·V S KostićS Janković
May 1, 1991·Journal of Affective Disorders·R R GoetzB Nelson
Jun 1, 1997·Journal of Psychosomatic Research·V S RotenbergA Elizur
Jan 1, 1994·Journal of Psychosomatic Research·C Idzikowski
Jan 1, 1994·Journal of Psychosomatic Research·P Sandor, C M Shapiro
Feb 9, 2013·Sleep Medicine Reviews·Laura PalaginiDieter Riemann
Jul 17, 2001·Biological Psychology·D RiemannU Voderholzer
May 1, 1995·The International Journal of Neuroscience·A N VgontzasA Vela-Bueno
Oct 25, 2013·International Review of Psychiatry·Adam WichniakWojciech Jernajczyk
Jan 1, 2006·International Journal of Psychiatry in Clinical Practice·Andrew G Mayers, David S Baldwin
Oct 27, 2012·Neurologic Clinics·Andrew D Krystal
Sep 19, 2009·Journal of Psychiatric Research·Axel Steiger, Mayumi Kimura
Feb 3, 2009·Psychiatry Research·Venkataramanujan SrinivasanDaniel P Cardinali
Jul 30, 2008·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Palmiero Monteleone, Mario Maj
Feb 7, 2007·Acta Psychiatrica Scandinavica. Supplementum·R Armitage
Sep 21, 2002·Biological Psychiatry·Sieglinde ModellChristoph J Lauer
Jan 6, 2005·Archives of Medical Research·Reyes Haro, René Drucker-Colín
Mar 1, 1989·Biological Psychiatry·D A WallerH P Roffwarg
Jan 1, 1992·Biological Psychiatry·R ArmitageD E Giles

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.